Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-27

Study Completion Date

2027-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus (HPV)-related cancers in women. RG1-VLP is a vaccine that aims to protect against rare HPV types not targeted by currently approved HPV vaccines. HPV is a common sexually-transmitted infection that can cause certain genital and oral cancers. RG1-VLP contains a protein of HPV type 16 (HPV16) with a slightly different structure than the licensed Gardasil-9 vaccine. Gardasil-9 is approved by the Federal Drug Administration to help protect against diseases caused by some types of HPV. Gardasil-9 also contains 9 different HPV proteins. Both vaccines contain alum to stimulate the immune system. The usual approach for the prevention of HPV-related cancers for patients who are at increased risk is to consider the currently approved HPV vaccine like Gardasil-9, as well as to be followed closely by their doctor to watch for the development of cancer via routine pap smears. This trial may allow researchers to find out whether the RG1-VLP vaccine can safely trigger an immune response against HPV in healthy women and if it is better or worse than the usual approach for the prevention of HPV-related cancers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

NCT00091130

Atypical Squamous Cells of Undetermined Significance Cervical Cancer High-grade Squamous Intraepithelial Lesion +1 more

COMPLETED PHASE2

A Phase I Clinical Trial of an HPV Therapeutic Vaccine

NCT01653249

Human Papillomavirus

COMPLETED PHASE1

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

NCT00520598

Cervical Cancer Vulvar Cancer Vaginal Cancer +2 more

COMPLETED PHASE2

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

NCT00541970

Infections, Papillomavirus

COMPLETED PHASE1

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

NCT02653118

Cervical Cancer Vulvar Cancer Vaginal Cancer +2 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. Assess the safety of RG1-virus-like particles (VLP) in healthy 18-60 years old women at 3 escalating doses.

SECONDARY OBJECTIVES:

I. Determine the immunogenicity of RG1-VLP in healthy 18-60 year old women at 3 escalating doses via the following assays:

Ia. Determine serum antibody responses induced by RG1-VLP vaccination by both human papillomavirus (HPV) 16 L1 VLP and HPV16 L2 RG1-peptide enzyme-linked immunosorbent assay (ELISA). This will be assessed at months 0, 1, 2, 3, 6, 7 and 12; Ib. Determine whether vaccination-induced serum antibody response neutralizes HPV16. This will be assessed at months 0, 1, 2, 3, 6, 7 and 12.

EXPLORATORY OBJECTIVES:

I. Determine whether vaccination-induced serum antibody response broadly neutralizes high risk (hr) HPV other than HPV16. This will be assessed at months 0, 1, 2, 3, 6, 7 and 12.

II. Determine whether vaccination induces a cell-mediated immune (CMI) response. Peripheral blood mononuclear cells (PBMC) will be isolated at months 0, 1 and 7.

III. Determine whether vaccination-induced serum antibody response upon passive transfer to naive animals, protects mice against hrHPV pseudovirion (PsV) challenge. This will be assessed at months 0 and 7.

IV. Determine whether vaccination results in changes in local antibody titers in vaginal and oral secretions (via oral rinse) and the effects of vaccination on HPV types in optionally-collected vaginal and oral secretions and eyebrow hair samples between months 0, 7 and 12.

V. Assess the safety of recombinant human papillomavirus nonavalent vaccine (Gardasil-9) in healthy women post-administration of RG1-VLP.

OUTLINE: This is a dose-escalation study of RG1-VLP.

Patients receive RG1-VLP intramuscularly (IM) for 3 doses at months 0, 2, and 6 in the absence of unacceptable toxicity. Patients may also receive Gardasil-9 via injection for 3 doses at 6 months after the 3rd study vaccination (month 12), then at months 14 and 18 in the absence of unacceptable toxicity. Patients also undergo blood sample collection on study and may undergo vaginal swab collection on study.

After completion of study treatment, patients are followed up to 6 months post-3rd RG1-VLP vaccination injection or up to 14 days post-3rd Gardasil-9 vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Papillomavirus-Related Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prevention (RG1-VLP, Gardasil-9)

Patients receive RG1-VLP IM for 3 doses at months 0, 2, and 6 in the absence of unacceptable toxicity. Patients may also receive Gardasil-9 via injection for 3 doses at 6 months after the 3rd study vaccination (month 12), then at months 14 and 18 in the absence of unacceptable toxicity. Patients also undergo blood sample collection on study and may undergo vaginal swab collection on study.

Group Type EXPERIMENTAL

Biospecimen Collection

Intervention Type PROCEDURE

Undergo blood sample and vaginal swab collection

HPV16 RG1 VLP Vaccine

Intervention Type BIOLOGICAL

Given IM

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Recombinant Human Papillomavirus Nonavalent Vaccine

Intervention Type BIOLOGICAL

Given via injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biospecimen Collection

Undergo blood sample and vaginal swab collection

Intervention Type PROCEDURE

HPV16 RG1 VLP Vaccine

Given IM

Intervention Type BIOLOGICAL

Questionnaire Administration

Ancillary studies

Intervention Type OTHER

Recombinant Human Papillomavirus Nonavalent Vaccine

Given via injection

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biological Sample Collection Biospecimen Collected Specimen Collection 16L1-16L2aa17-36-based Vaccine HPV16 RG1-VLP HPV16-RG1VLPs RG1-VLP Vaccine RG1-VLPs Gardasil 9 Nonavalent HPV VLP Vaccine Recombinant HPV Nonavalent Vaccine Recombinant Human Papillomavirus 9-valent Vaccine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women, age 18 - 60 years. Because no dosing or adverse event (AE) data is currently available for the use of RG1-VLP in humans, children and adolescents are excluded from this study
* White blood cell (WBC) between 3000/mm\^3 - institutional upper limit of normal
* Hemoglobin (Hgb) between 10 g/dl - institutional upper limit of normal
* Platelets \>= 100,000/mm\^3
* Serum creatinine within institutional normal limits
* Bilirubin =\< 2x institutional upper limit of normal
* Alanine aminotransferase (ALT) =\< 2x institutional upper limit of normal
* Aspartate aminotransferase (AST) =\< 2x institutional upper limit of normal
* Human immunodeficiency virus (HIV)-1/HIV-2 negative
* Hepatitis B and hepatitis C negative
* The effects of RG1-VLP vaccination on the developing human fetus at the proposed doses are unknown. For this reason, all women of childbearing potential will have a pregnancy test and all heterosexually active women must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
* The following persons are not considered to be able to bear children and are therefore eligible to participate without the use of concurrent birth control:

* Female with bilateral oophorectomy and/or hysterectomy
* Female with fallopian tubes cut, tied or sealed
* Female with sterilization implant (e.g. Adiana, Essure) placed \> 3 months prior to randomization
* Female post-menopausal (\> 1 year since last menses or prior laboratory follicle stimulating hormone \[FSH\] value per institutional range indicating post-menopausal)
* Eastern Cooperative Oncology Group (ECOG) performance status of =\< 1
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

* History of any of the following:

* Prior or current genital warts
* Treatment for anogenital intraepithelial neoplasia (cervical intraepithelial neoplasia \[CIN\], anal intraepithelial neoplasia \[AIN\], vaginal intraepithelial neoplasia \[VAIN\], vulvar intraepithelial neoplasia \[VIN\])
* Systemic cancer treatment within the prior year
* History of anaphylaxis to vaccines
* Any prior vaccination with Gardasil, Gardasil-9, or Cervarix or other HPV vaccine
* Receipt of blood products within 3 months of enrollment, or continuing plasma donation
* Participants receiving any other investigational agents
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the adjuvant or to RG1-VLP
* Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements or preclude protocol vaccination
* Pregnant women or actively lactating women are excluded from this study because RG1-VLP is a vaccine with the potential for teratogenic or abortifacient effects
* Planned receipt of any inactivated vaccine in the 2 weeks preceding and the 2 weeks following any trial vaccination
* Planned receipt of any live attenuated vaccine in the 4 weeks preceding and the 4 weeks following any trial vaccination
* Women with a history of bleeding disorders or use of anticoagulants (aspirin is acceptable)
* Had prior medical diagnoses:

* Rheumatoid arthritis or other auto-immune disease
* Congenital or acquired immunodeficiency
* Collagen vascular disease
* Following medical treatments:

* Current use of immunosuppressive drugs including corticosteroid use (inhaled or topical steroids are permitted)
* Unrecovered major infections and/or surgical procedures

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Reinhard Kirnbauer

Role: PRINCIPAL_INVESTIGATOR

Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, United States

Site Status WITHDRAWN

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, United States

Site Status WITHDRAWN

Staten Island University Hospital

Staten Island, New York, United States

Site Status WITHDRAWN

University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, United States

Site Status RECRUITING

Medical University Vienna

Vienna, , Austria

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Austria

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Reinhard Kirnbauer

Role: primary

[email protected]

Reinhard Kirnbauer

Role: primary

[email protected]

43 1 40400 Ext. 77680